Published in Nat Med on August 04, 2011
Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia. Pediatr Cardiol (2012) 0.85
Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular Cardiomyocytes. PLoS One (2015) 0.81
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med (1989) 9.08
Sudden cardiac death in the United States, 1989 to 1998. Circulation (2001) 7.92
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med (2009) 3.35
Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. J Mol Cell Cardiol (2009) 2.98
Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation (2003) 2.57
Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest (2008) 2.45
Kinetics of FKBP12.6 binding to ryanodine receptors in permeabilized cardiac myocytes and effects on Ca sparks. Circ Res (2010) 2.29
Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol (2011) 1.89
Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med (2011) 1.88
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol (2011) 1.44
Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol (2007) 1.24
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med (2009) 3.35
Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. J Mol Cell Cardiol (2009) 2.98
Modest reductions of cardiac calsequestrin increase sarcoplasmic reticulum Ca2+ leak independent of luminal Ca2+ and trigger ventricular arrhythmias in mice. Circ Res (2007) 2.18
Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest (2008) 2.02
Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol (2011) 1.89
Ablation of triadin causes loss of cardiac Ca2+ release units, impaired excitation-contraction coupling, and cardiac arrhythmias. Proc Natl Acad Sci U S A (2009) 1.57
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol (2011) 1.44
Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro. Circulation (2011) 1.38
Teaching rational prescribing: a new clinical pharmacology curriculum for medical schools. Naunyn Schmiedebergs Arch Pharmacol (2002) 1.29
F110I and R278C troponin T mutations that cause familial hypertrophic cardiomyopathy affect muscle contraction in transgenic mice and reconstituted human cardiac fibers. J Biol Chem (2005) 1.28
Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants. Circ Res (2014) 1.27
Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. Eur J Heart Fail (2005) 1.26
Myofilament Ca sensitization increases cytosolic Ca binding affinity, alters intracellular Ca homeostasis, and causes pause-dependent Ca-triggered arrhythmia. Circ Res (2012) 1.23
Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. J Mol Cell Cardiol (2011) 1.19
Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia. Cardiovasc Res (2013) 1.17
Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy. J Electrocardiol (2011) 1.16
Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility. J Mol Cell Cardiol (2010) 1.11
Calsequestrin 2 and arrhythmias. Am J Physiol Heart Circ Physiol (2011) 1.08
Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm (2012) 1.06
Genetics of sudden cardiac death syndromes. Curr Opin Cardiol (2011) 1.02
Differential effect of troponin T mutations on the inotropic responsiveness of mouse hearts--role of myofilament Ca2+ sensitivity increase. J Physiol (2006) 0.98
The calsequestrin mutation CASQ2D307H does not affect protein stability and targeting to the junctional sarcoplasmic reticulum but compromises its dynamic regulation of calcium buffering. J Biol Chem (2009) 0.97
Ryanodine receptor inhibition potentiates the activity of Na channel blockers against spontaneous calcium elevations and delayed afterdepolarizations in Langendorff-perfused rabbit ventricles. Heart Rhythm (2012) 0.94
Amitriptyline activates cardiac ryanodine channels and causes spontaneous sarcoplasmic reticulum calcium release. Mol Pharmacol (2008) 0.93
Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients. Circ Res (2013) 0.91
Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments. Circ Res (2013) 0.89
Coordinated regulation of murine cardiomyocyte contractility by nanomolar (-)-epigallocatechin-3-gallate, the major green tea catechin. Mol Pharmacol (2012) 0.89
Suppression of spontaneous ca elevations prevents atrial fibrillation in calsequestrin 2-null hearts. Circ Arrhythm Electrophysiol (2014) 0.88
Mechanism of antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia. Circ Res (2011) 0.87
Power and pitfalls of using transgenic mice to optimize therapy for CPVT: a need for prospective placebo-controlled clinical trials in genetic arrhythmia disorders. Heart Rhythm (2010) 0.85
Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia. Pediatr Cardiol (2012) 0.85
Cardiac calsequestrin: the new kid on the block in arrhythmias. J Cardiovasc Electrophysiol (2009) 0.83
Functional consequences of stably expressing a mutant calsequestrin (CASQ2D307H) in the CASQ2 null background. Am J Physiol Heart Circ Physiol (2011) 0.81
Inositol 1,4,5-trisphosphate receptors: "exciting" players in cardiac excitation-contraction coupling? Circulation (2013) 0.81
Oxidized CaMKII: a "heart stopper" for the sinus node? J Clin Invest (2011) 0.80
Dantrolene: from better bacon to a treatment for ventricular fibrillation. Circulation (2014) 0.79
Myofilament calcium de-sensitization and contractile uncoupling prevent pause-triggered ventricular tachycardia in mouse hearts with chronic myocardial infarction. J Mol Cell Cardiol (2013) 0.78
Gauging the risk of arrhythmic death by common genetic variants: resurgence of the sinister QT. Circ Cardiovasc Genet (2011) 0.78
Triadin regulates cardiac muscle couplon structure and microdomain Ca(2+) signalling: a path towards ventricular arrhythmias. Cardiovasc Res (2013) 0.78
Ratiometric imaging of calcium during ischemia-reperfusion injury in isolated mouse hearts using Fura-2. Biomed Eng Online (2012) 0.77
Genesis of the monophasic action potential: role of interstitial resistance and boundary gradients. Am J Physiol Heart Circ Physiol (2003) 0.77
Familial hypertrophic cardiomyopathy: is the Frank-Starling law kaput? Circ Res (2013) 0.76
The beat goes on--driven by a cardiac calcium clock? Heart Rhythm (2008) 0.75
Exercise after myocardial infarction improves contractility and decreases myofilament Ca2+ sensitivity. Circ Res (2007) 0.75
Triadin: the new player on excitation-contraction coupling block. Circ Res (2005) 0.75
Calcium in atrial fibrillation - pulling the trigger or not? J Clin Invest (2014) 0.75
Calmodulin Mutants Linked to Catecholaminergic Polymorphic Ventricular Tachycardia Fail to Inhibit Human RyR2 Channels. J Am Coll Cardiol (2017) 0.75